DiffBind

DiffBind is a computational tool used to analyze genome-wide data sets and identify genes involved in specific biological processes or diseases. It can be used to identify genetic variations associated with disease outcomes, such as response to treatment, and to predict patient outcomes based on those variations. The tool uses various algorithms and statistical methods to analyze large amounts of data and generate insights into complex biological systems.
DiffBind includes the following steps:
Peak Calling: Before using DiffBind, ChIP-seq data is typically processed to identify peaks, representing regions of the genome where the DNA-associated protein of interest is enriched.
Binding Site Overlap: DiffBind works with a set of identified peaks from different experimental conditions. It assesses the overlap of binding sites (peaks) across samples.
Statistical Testing: Statistical tests are performed to identify differential binding between different conditions. DiffBind uses methods like DESeq2 or edgeR for statistical testing.
Normalization: The tool may perform normalization to account for differences in library size or sequencing depth between samples.
Results: The final output includes a list of differentially bound sites and associated statistical metrics such as p-values and fold changes.

Topic

ChIP-seq

Detail

  • Operation: Differential binding analysis

  • Software interface: Command-line user interface,Library

  • Language: R

  • License: Artistic License 2.0

  • Cost: Free

  • Version name: 3.12.0

  • Credit: The Eugenio Rodríguez Pascual Foundation, the Government of Catalonia, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, the Red Cooperative Research Thematic Network on Cancer (RTICC), the Spanish Ministry of Health, Fund for Health Research–Institute of Health Carlos III.

  • Input: -

  • Output: -

  • Contact: Rory Stark bioconductor@starkhome.com

  • Collection: -

  • Maturity: Mature

Publications

  • VAV3 mediates resistance to breast cancer endocrine therapy.
  • Aguilar H, et al. VAV3 mediates resistance to breast cancer endocrine therapy. VAV3 mediates resistance to breast cancer endocrine therapy. 2014; 16:R53. doi: 10.1186/bcr3664
  • https://doi.org/10.1186/bcr3664
  • PMID: 24886537
  • PMC: PMC4076632

Download and documentation


< Back to DB search